The FDA Moves To Restrict Monoclonal Antibody Treatments

The F.D.A. continues to target alternative treatments to Covid-19.

A quick Google search will reveal that roughly 40% of the agency’s revenues come from the very companies they are meant to regulate, and regulatory cross-play exists between the agency and the upper echelons of the private sector.

The agency came under heavy scrutiny when it requested 75 years to release vaccine data—a request that was recently shot down by a federal judge.

Knowing all of this information, it is hard to think of the agency as impartial or having the best interests of the American people in mind.

According to the latest reports, F.D.A. officials will sharply restrict the usage of at least 2 monoclonal antibody treatments for Covid-19, as the agency continues to push vaccines as the only viable solution to the Covid-19 pandemic.

This is despite the fact that vaccines do not stop transmission of the virus, and have been linked to a number of concerning adverse reports.

The F.D.A. continues its war on alternative Covid-19 treatments, but sharp criticism of the agency continues to shake confidence in its viability as a functioning regulatory body:

As a result of the @US_FDA's abrupt decision to remove the EUAs for two monoclonal antibodies, monoclonal antibody treatment sites will be closed until further notice. Full press release is below. pic.twitter.com/RGeWTPwxCs

— Florida Dept. of Health (@HealthyFla) January 25, 2022

https://twitter.com/kylenabecker/status/1486007554874486792

According to The Washington Post:

Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement that data show the two antibody treatments “are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States.”

Omicron is responsible for more than 99 percent of cases in the United States, according to the Centers for Disease Control and Prevention.

 

Florida's current death rate is less than half of New York, in case you were wondering why the FDA changed the rules on monoclonal antibodies. These people are evil.

— thebradfordfile (@thebradfordfile) January 25, 2022

https://twitter.com/rising_serpent/status/1486010148426559494

CNN echoed The Washington Post:

The US Food and Drug Administration could decide in the coming days to take steps to curb the use of antibody treatments produced by Eli Lilly and Regeneron, the source said, pointing to the growing body of evidence that shows their monoclonal therapies don’t effectively neutralize the virus’ Omicron variant.